Abstract: Ma Xiaolei, Gao Na, Liu Zhengyi, Zhang Jianzhong Department of Dermatology, Peking University People′s Hospital, Beijing 100044, China （Ma XL, Zhang JZ）; Peking University International Hospital, Beijing 102206, China （Ma XL, Gao N, Liu ZY） Corresponding author: Zhang Jianzhong, Email: rmzjz@126.com 【Abstract】 Objective To detect levels of interleukin-4 （IL-4）, IL-10, interferon-γ （INF-γ） and transforming growth factor-β （TGF-β） in the culture supernatant of peripheral blood mononuclear cells （PBMCs） from patients with atopic dermatitis （AD）, and to evaluate regulatory effects of benvitimod on these cytokines. Methods PBMCs were isolated from 20 AD patients and 20 healthy controls. Then, PBMCs from AD patients were equally divided into 4 groups to be cultured with phosphate-buffered saline （PBS group）, 400 nmol/L benvitimod solution （benvitimod group）, 250 nmol/L dexamethasone solution （dexamethasone group） and 10 nmol/L tacrolimus solution （tacrolimus group）, respectively. Enzyme-linked immunosorbent assay （ELISA） was performed to detect levels of IL-4, IL-10, INF-γ and TGF-β in the culture supernatant of PBMCs. Results Compared with healthy controls, patients with AD showed significantly higher level of IL-4 （83.4 ± 12.2 vs. 44.3 ± 5.7 pg/ml, P < 0.05）, but lower levels of INF-γ （12.5 ± 2.3 vs. 25.4 ± 3.4 pg/ml, P < 0.05） and IL-10 （144.4 ± 4.1 vs. 189.9 ± 6.5 pg/ml, P < 0.05） in peripheral blood. However, no significant difference in the level of TGF-β was observed between the patient group and control group （178.9 ± 17.40 vs. 158.7 ± 18.30 pg/ml, P > 0.05）. Compared with PBS, 400 nmol/L benvitimod could decrease the of IL-4 （50.2 ± 10.1 vs. 83.3 ± 12.2 pg/ml, P < 0.05）, IL-10 （124.7 ± 17.5 vs. 144.4 ± 4.1 pg/ml, P > 0.05） and INF-γ （9.56 ± 5.1 vs. 12.5 ± 2.3 pg/ml, P > 0.05）, but increase the of TGF-β （203.6 ± 15.3 vs. 178.9 ± 17.4 pg/ml, P > 0.05） by PBMCs. In addition, no significant differences in the of IL-4, IL-10, INF-γ or TGF-β were observed between the benvitimod group and dexamethasone group or tacrolimus group （all P > 0.05）. Conclusion Benvitimod can regulate the of IL-4, IL-10, INF-γ and TGF-β by PBMCs in patients with AD.